CIPO trademark

VYGLEA

RegisteredCIPOWord markClass 5

"VYGLEA" is a word mark owned by Biohaven Therapeutics Ltd., filed at the CIPO on June 27, 2023. It is registered and covers class 5 (Pharmaceuticals).

Official CIPO record
VYGLEA
Word mark as filed with the CIPO
Status
Registered
Since December 5, 2025
Filed
June 27, 2023
Registered
December 5, 2025
Expires
December 5, 2035
Application no.
2266135
Registration no.
TMA1364990
Office
CIPO
Canadian Intellectual Property Office
Mark type
Word mark
1 class
Ownership

Who owns VYGLEA

The owner on file, matched to the company behind it. Every owner-name spelling for that company is grouped on its page.

Goods and services

What the mark covers

The products and services VYGLEA is filed for, grouped by Nice class.

  • Medicated and pharmaceutical preparations, both prescription and over-the-counter, for the treatment of central nervous system disorders, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, epilepsy, neurologic illnesses in the nature of brain injury, spinal cord injury, seizure disorders, and psychiatric illnesses in the nature of anxiety disorder, depression, Bipolar Disorder, Post-Traumatic Stress Disorder (PTSD), Schizophrenia, Eating Disorders, disruptive behaviour, dissocial disorders, Neurodevelopmental disorders, for the treatment of brain ischemia, post-stroke recovery, severe intracranial atherosclerosis, carotid endarterectomy, cardiac bypass, cerebral vasculitis, reversible cerebral vasoconstriction syndrome, for the treatment of neurodegenerative diseases, in the nature of Alzheimer's disease (AD), Amyotrophic Lateral Sclerosis (ALS), Huntington's disease, Lewy body dementia, frontotemporal dementia, vascular dementia, Parkinson's disease, cognitive impairment of aging, progressive Multiple Sclerosis, for the treatment of pain, in the nature of opioid sparing analgesia, chronic neuropathic pain, peripheral neuropathy, low back pain in the nature of failed back surgery syndrome, radiculopathy in the nature of sciatica, diabetic peripheral neuropathy, post-herpetic neuralgia, medication induced neuropathies, complex regional pain syndrome, fibromyalgia, chronic post-operative pain, cluster thoracotomy, phantom limb, stump neuroma, for the treatments of degenerative diseases, in the nature of breath holding in Rett syndrome, dystonias, dysphagia, gait abnormalities, bulbar function in ALS, pseudobulbar affect, levodopa-induced dyskinesias in Parkinson's disease, agitation in AD, disinhibition in dementia, for the treatment of neuropsychiatric disorders, in the nature of treatment resistant depression, Post Traumatic Stress Disorder (PTSD) in the nature of hyperarousal, substance abuse disorders, addiction disorders, Obsessive Compulsive Disorder (OCD), hoarding, trichotillomania, eating disorders, Generalized Anxiety Disorder (GAD), adjustment disorders, panic disorder, major depressive episode, bipolar disorder in the nature of manic and depressive episodes, dysthymia, cyclothymia, psychotic disorders, schizophrenia, for the treatment of cancer, for the treatment of cerebellar disorders, in the nature of spinocerebellar ataxia, Friedriech's ataxia, multisystem atrophy, essential tremor, for the treatment of brain and cord injuries, in the nature of post-intracranial hemorrhage recovery, traumatic brain injury, spinal cord injury, for the treatment of optic and retinal neuropathies, in the nature of glaucoma, diabetic retinopathy, ischemic optic and retinal neuropathies, for the treatment of headache and facial pain, in the nature of headache, migraine, chronic daily headache, cluster headache, trigeminal neuralgia, for the treatment of hearing disorders, tinnitus, delirium, sleep disorders, parasomnias, learning disorders, Attention Deficit Disorder (ADD), Pervasive Developmental Disorders (PDD), Asperger's syndrome, autism, menopausal hot flashes.

History

What has happened so far

Steps recorded by the CIPO, newest first.

  1. Agent Changed; Transferred From: 5784 To: 59
  2. Registered
  3. Registration Pending
  4. Advertised; Vol.72 Issue 3699
  5. Approval Notice Sent; APPROVED BY PROGRAM EX200M1
  6. Approved; APPROVED BY PROGRAM EX200M1
  7. Examiner's First Report
  8. Search Recorded
  9. Agent Name Changed
  10. Pre-Assessment Letter Sent; Goods or Services Not Acceptable

3 earlier steps on the official record.

FAQ

About VYGLEA

Who owns the trademark "VYGLEA"?

The CIPO trademark "VYGLEA" (application 2266135) is owned by Biohaven Therapeutics Ltd.

What is the status of "VYGLEA"?

Its status at the CIPO is: registered.

When was "VYGLEA" registered?

It was registered on December 5, 2025 and is due to expire on December 5, 2035.

API

Get this data via the API

Everything on this page comes from the Signa API. Pull VYGLEA and marks like it into your own product with one request.

  • GET/v1/trademarks/{id}

    The full record: owners, classes, dates and images

  • GET/v1/trademarks/{id}/events

    Every step in the office history

  • GET/v1/proceedings?trademark_id={id}

    Oppositions and cancellations against the mark

GET /v1/trademarks/{id}
ID=tm_019deb34-fc01-7683-96e0-f37437706baf
curl https://api.signa.so/v1/trademarks/$ID \
  -H "Authorization: Bearer $SIGNA_API_KEY"
Response
{
  "id": "tm_019deb34-fc01-7683-96e0-f37437706baf",
  "object": "trademark",
  "mark_text": "VYGLEA",
  "status": {
    "primary": "active",
    "stage": "registered"
  },
  "office_code": "CA",
  "application_number": "2266135",
  "filing_date": "2023-06-27",
  "nice_classes": [
    5
  ],
  "owners": [
    {
      "name": "Biohaven Therapeutics Ltd.",
      "entity_id": "ent_019eb7d2-fb5b-7654-8bb0-d58ab7c6ce1e"
    }
  ]
}